PA5-47565

antibody from Invitrogen Antibodies

Targeting: MYF5 bHLHc2

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-47565

Provider

Invitrogen Antibodies

Product name

MYF5 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

This antibody detects recombinant human MYF-5 in direct ELISAs and Western blots. Reconstitute at 0.2 mg/mL in sterile PBS.

Reactivity

Human, Mouse

Host

Goat

Isotype

IgG

Vial size

100 µg

Concentration

0.2 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models.

Vallecillo-Zúniga ML, Rathgeber MF, Poulson PD, Hayes S, Luddington JS, Gill HN, Teynor M, Kartchner BC, Valdoz J, Stowell C, Markham AR, Arthur C, Stowell S, Van Ry PM
PloS one 2020;15(9):e0238441

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry analysis of MYF5 in immersion fixed C2C12 mouse myoblast cell line undifferentiated (upper panel) or differentiated with horse serum for 7 days (lower panel). Samples were incubated in MYF5 polyclonal antibody (Product # PA5-47565) using a dilution of 10 µg/mL for 3 hours at room temperature followed by NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red) and counterstained with DAPI (blue).

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemical analysis of MYF-5 was detected in immersion fixed C2C12 mouse myoblast cell line undifferentiated (upper panel) or differentiated with horse serum for 7 days (lower panel) using Goat Anti-human/mouse MYF-5 Antigen Affinity-purified Polyclonal Antibody (Product # PA5-47565) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the 557-conjugated Anti-Goat IgG Secondary Antibody (re and counterstained with DAPI (blue).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig 1 rHsGal-1 increases myogenic regulatory factors in A/J -/- myotubes. A. Quantification of myogenin after 72h treatment with varying concentrations of rHsGal-1. B. Western blot images of myogenin at different rHsGal-1 treatments. C-F. Quantification of myogenic markers MHC(C), Pax7(D), MyoD(E), and Myf5(F) in A/J -/- myotubes after 72h treatment with 0.11muM rHsGal-1. G-H. Quantification of Gal-1(G) and His.H8(H)in A/J -/- myotubes after 72h treatment with 0.11muM rHsGal-1. I. Western blot images of myogenic markers (Pax7, Myf5, MyoD, and MHC) and of mouse Gal-1 and His Tagged rHsGal-1. J. RT-qPCR quantification of LGALS1 transcript between A/J WT, A/J -/- NT, and A/J -/- 0.11muM rHsGal-1 treated myotubes. p values are measured by Tukey's multiple comparison test and indicated by *p< 0.05, **p< 0.01, ****p< 0.0001 (n = 3 for each group). Error bars represent SEM.